EP3057594A4 - Méthode de traitement du cancer - Google Patents

Méthode de traitement du cancer Download PDF

Info

Publication number: EP3057594A4
Authority: EP; European Patent Office
Prior art keywords: treating cancer; cancer; treating
Prior art date: 2013-10-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP14854576.7A

Other languages

German (de)

English (en)

Other versions

EP3057594A1 (fr

Inventor

Heike KEILHACK

Sarah K. Knutson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eisai R&D Management Co Ltd

Epizyme Inc

Original Assignee

Eisai R&D Management Co Ltd

Epizyme Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-10-18

Filing date

2014-10-17

Publication date

2017-06-07

2014-10-17 Application filed by Eisai R&D Management Co Ltd, Epizyme Inc filed Critical Eisai R&D Management Co Ltd

2016-08-24 Publication of EP3057594A1 publication Critical patent/EP3057594A1/fr

2017-06-07 Publication of EP3057594A4 publication Critical patent/EP3057594A4/fr

Status Pending legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP14854576.7A 2013-10-18 2014-10-17 Méthode de traitement du cancer Pending EP3057594A4 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201361893031P	2013-10-18	2013-10-18
US201361912938P	2013-12-06	2013-12-06
US201462064894P	2014-10-16	2014-10-16
PCT/US2014/061205 WO2015058125A1 (fr)	2013-10-18	2014-10-17	Méthode de traitement du cancer

Publications (2)

Publication Number	Publication Date
EP3057594A1 EP3057594A1 (fr)	2016-08-24
EP3057594A4 true EP3057594A4 (fr)	2017-06-07

Family

ID=52828762

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP14854576.7A Pending EP3057594A4 (fr)	2013-10-18	2014-10-17	Méthode de traitement du cancer

Country Status (5)

Country	Link
US (5)	US20160228447A1 (fr)
EP (1)	EP3057594A4 (fr)
JP (1)	JP2016533364A (fr)
AU (3)	AU2014337121A1 (fr)
WO (1)	WO2015058125A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014062720A2 (fr)	2012-10-15	2014-04-24	Epizyme, Inc.	Méthodes de traitement du cancer
CN105873592B (zh)	2013-12-06	2023-01-31	Epizyme股份有限公司	用于治疗癌症的组合疗法
KR20230031963A (ko)	2014-06-17	2023-03-07	에피자임, 인코포레이티드	림프종 치료를 위한 ｅｚｈ2 억제제
SG11201702488YA (en)	2014-10-16	2017-04-27	Epizyme Inc	Method for treating cancer
DK3220916T3 (da)	2014-11-17	2023-06-26	Epizyme Inc	Fremgangsmåde til behandling af cancer med n-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamid
EP3285773A4 (fr)	2015-04-20	2019-04-10	Epizyme, Inc.	Polythérapie pour le traitement du cancer
CA2988816A1 (fr)	2015-06-10	2016-12-15	Epizyme, Inc.	Inhibiteurs d'ezh2 pour traiter le lymphome
US10493076B2 (en)	2015-08-24	2019-12-03	Epizyme, Inc.	Method for treating cancer
TW201718598A (zh)	2015-08-27	2017-06-01	美國禮來大藥廠	Ｅｚｈ２抑制劑
AU2016355523A1 (en)	2015-11-16	2018-06-07	Enrique GARCIA-RIVERA	Compounds and methods for treating synovial sarcomas
WO2017132518A1 (fr)	2016-01-29	2017-08-03	Epizyme, Inc.	Polythérapie pour le traitement du cancer
AU2017273726B2 (en)	2016-06-01	2023-10-19	Epizyme, Inc.	Use of EZH2 inhibitors for treating cancer
JP2019521988A (ja)	2016-06-17	2019-08-08	エピザイム，インコーポレイティド	癌を処置するためのｅｚｈ２阻害剤
KR101913693B1 (ko)	2016-12-14	2018-10-31	사회복지법인 삼성생명공익재단	SS18-SSX 융합 유전자 특이적 siRNA 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물
WO2018183885A1 (fr)	2017-03-31	2018-10-04	Epizyme, Inc.	Multithérapie pour le traitement du cancer
CN110944628A (zh)	2017-06-02	2020-03-31	Epizyme股份有限公司	使用ezh2抑制剂治疗癌症
US11452727B2 (en)	2017-09-05	2022-09-27	Epizyme, Inc.	Combination therapy for treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050107290A1 (en) *	2003-06-27	2005-05-19	Fujisawa Pharmaceutical Co. Ltd.	Therapeutic agent for soft tissue sarcoma
WO2013138361A1 (fr) *	2012-03-12	2013-09-19	Epizyme, Inc.	Inhibiteurs de ezh2 humain et procédés d'utilisation associés
WO2013155317A1 (fr) *	2012-04-13	2013-10-17	Epizyme, Inc.	Forme saline d'un inhibiteur de l'histone méthyltransférase humaine ezh2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2870010C (fr) *	2012-04-13	2023-02-21	Epizyme, Inc.	Polytherapie anticancereuse
WO2014062720A2 (fr) *	2012-10-15	2014-04-24	Epizyme, Inc.	Méthodes de traitement du cancer

2014
- 2014-10-17 EP EP14854576.7A patent/EP3057594A4/fr active Pending
- 2014-10-17 WO PCT/US2014/061205 patent/WO2015058125A1/fr active Application Filing
- 2014-10-17 US US15/029,914 patent/US20160228447A1/en not_active Abandoned
- 2014-10-17 JP JP2016523248A patent/JP2016533364A/ja active Pending
- 2014-10-17 AU AU2014337121A patent/AU2014337121A1/en not_active Abandoned
2017
- 2017-04-25 US US15/496,653 patent/US20180071300A1/en not_active Abandoned
2019
- 2019-01-02 US US16/237,867 patent/US20190240230A1/en not_active Abandoned
2020
- 2020-02-12 AU AU2020200994A patent/AU2020200994A1/en not_active Abandoned
- 2020-04-06 US US16/841,097 patent/US20200330472A1/en not_active Abandoned
2021
- 2021-11-04 AU AU2021261904A patent/AU2021261904A1/en not_active Abandoned
- 2021-12-21 US US17/557,649 patent/US20220218714A1/en not_active Abandoned

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050107290A1 (en) *	2003-06-27	2005-05-19	Fujisawa Pharmaceutical Co. Ltd.	Therapeutic agent for soft tissue sarcoma
WO2013138361A1 (fr) *	2012-03-12	2013-09-19	Epizyme, Inc.	Inhibiteurs de ezh2 humain et procédés d'utilisation associés
WO2013155317A1 (fr) *	2012-04-13	2013-10-17	Epizyme, Inc.	Forme saline d'un inhibiteur de l'histone méthyltransférase humaine ezh2

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CIGALL KADOCH ET AL: "Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX Oncogenic Fusion in Synovial Sarcoma", CELL, vol. 153, no. 1, 1 March 2013 (2013-03-01), US, pages 71 - 85, XP055337550, ISSN: 0092-8674, DOI: 10.1016/j.cell.2013.02.036 *
ROBERTA CIARAPICA ET AL: "Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications", BMC MEDICINE, BIOMED CENTRAL LTD., LONDON, GB, vol. 9, no. 1, 25 May 2011 (2011-05-25), pages 63, XP021100856, ISSN: 1741-7015, DOI: 10.1186/1741-7015-9-63 *
See also references of WO2015058125A1 *

Also Published As

Publication number	Publication date
JP2016533364A (ja)	2016-10-27
US20220218714A1 (en)	2022-07-14
EP3057594A1 (fr)	2016-08-24
US20200330472A1 (en)	2020-10-22
US20180071300A1 (en)	2018-03-15
AU2021261904A1 (en)	2021-12-02
AU2020200994A1 (en)	2020-02-27
AU2014337121A1 (en)	2016-04-14
WO2015058125A1 (fr)	2015-04-23
US20160228447A1 (en)	2016-08-11
US20190240230A1 (en)	2019-08-08

Publication	Publication Date	Title
IL272905A (en)	2020-04-30	Methods of treating pancreatic cancer
EP3057594A4 (fr)	2017-06-07	Méthode de traitement du cancer
EP2964028A4 (fr)	2017-06-07	Composés pour le traitement du cancer
EP2968254A4 (fr)	2017-03-15	Procédés de traitement du cancer du poumon
EP3060207A4 (fr)	2017-04-12	Méthodes et compositions pour le traitement du cancer
HK1220155A1 (zh)	2017-04-28	治療癌症的方法
HK1213817A1 (zh)	2016-07-15	治療癌症的方法
EP2970419B8 (fr)	2019-12-11	Méthodes de traitement du cancer colorectal
HK1211322A1 (en)	2016-05-20	Methods of treating pancreatic cancer
EP3008212A4 (fr)	2017-05-24	Méthodes de traitement du cancer
EP3074040A4 (fr)	2017-06-28	Méthode de traitement du cancer
EP3004395A4 (fr)	2017-01-04	Compositions et méthodes pour le traitement du cancer
EP3011013A4 (fr)	2017-03-15	Procédé pour le traitement d'un cancer de l'ovaire
EP3057593A4 (fr)	2017-03-08	Traitement du cancer du pancréas
HUE048625T2 (hu)	2020-08-28	Módszer rák kezelésére
HK1219513A1 (zh)	2017-04-07	治療癌症的方法
HK1223547A1 (zh)	2017-08-04	癌症治療方法
EP3074038A4 (fr)	2017-08-02	Méthode de traitement de la néphropathie diabétique
EP3082860A4 (fr)	2017-08-16	Procédé de traitement de plaies
EP2984185A4 (fr)	2017-01-25	Procédés et compositions pour le traitement du cancer
EP3049078A4 (fr)	2017-05-10	Traitement du cancer
EP3007712A4 (fr)	2017-01-18	Traitement du cancer
EP3016948B8 (fr)	2017-07-19	2-acylaminothiazoles pour le traitement de cancer
WO2014160368A9 (fr)	2014-12-11	Compositions et méthodes pour le traitement du cancer
AU2013904620A0 (en)	2013-12-12	Method of treating cancer

Legal Events

Date	Code	Title	Description
2016-07-22	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-08-24	17P	Request for examination filed	Effective date: 20160429
2016-08-24	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-08-24	AX	Request for extension of the european patent	Extension state: BA ME
2017-06-07	A4	Supplementary search report drawn up and despatched	Effective date: 20170509
2017-06-07	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 35/00 20060101ALI20170502BHEP Ipc: A61K 31/5377 20060101AFI20170502BHEP Ipc: A61K 31/4412 20060101ALI20170502BHEP Ipc: A61K 31/444 20060101ALI20170502BHEP
2018-01-25	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2019-02-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2019-03-13	17Q	First examination report despatched	Effective date: 20190207
2020-12-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2021-06-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2023-11-22	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20231017